IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response [0.03%]
IHCH9033，一个新型的一类HDAC抑制剂，通过增强DNA损伤反应与FLT3抑制剂协同作用并拯救FLT3-ITD AML中的quizartinib抵抗性
Mingyue Yao,Wenzhong Yan,Yafang Wang et al.
Mingyue Yao et al.
Background: Despite initial success with FLT3 inhibitors (FLT3is), outcomes for FLT3-ITD acute myeloid leukemia (AML) patients remain unsatisfactory, underscoring the need for more effective treatment options. Epigenetic ...
Distinct response to IL-1β blockade in liver- and lung-specific metastasis mouse models of pancreatic cancer with heterogeneous tumor microenvironments [0.03%]
具有异质性肿瘤微环境的胰腺癌肝特异性及肺特异性转移小鼠模型对IL-1β阻断的不同反应
Sophia Y Chen,Heng-Chung Kung,Birginia Espinoza et al.
Sophia Y Chen et al.
Background: Pancreatic ductal adenocarcinoma (PDAC) is characterized by a heterogeneous tumor microenvironment (TME). The mechanism by which this heterogeneity confers resistance against immunotherapy remains unclear. Int...
CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells [0.03%]
CAR-巨噬细胞靶向CD26以消除慢性髓细胞性白血病干细胞
Jiang Guoyun,Qin Yuefeng,Huang Zhenglan et al.
Jiang Guoyun et al.
Background: Chronic myeloid leukemia stem cells (CML-LSCs), which exhibit resistance to tyrosine kinase inhibitors (TKIs), are the leading cause of treatment failure and recurrence in chronic myeloid leukemia (CML). This ...
Targeting secretory autophagy in solid cancers: mechanisms, immune regulation and clinical insights [0.03%]
靶向实体瘤中的分泌性自噬：机制、免疫调节和临床见解
Xinyu Li,Haiying Zhao
Xinyu Li
Secretory autophagy is a classical form of unconventional secretion that integrates autophagy with the secretory process, relying on highly conserved autophagy-related molecules and playing a critical role in tumor progression and treatment...
Applications of liposomes and lipid nanoparticles in cancer therapy: current advances and prospects [0.03%]
脂质体和脂质纳米颗粒在癌症治疗中的应用：现状与前景
Zhe Cheng,Huichao Huang,Meilong Yin et al.
Zhe Cheng et al.
Liposomes and lipid nanoparticles are common lipid-based drug delivery systems and play important roles in cancer treatment and vaccine manufacture. Although significant progress has been made with these lipid-based nanocarriers in recent y...
A non-conditioned bone marrow transplantation mouse model to study clonal hematopoiesis and myeloid malignancies [0.03%]
一种研究克隆造血和髓系恶性肿瘤的非条件性骨髓移植小鼠模型
Sofia Bentivegna,Marwa Almosailleakh,Lin-Pierre Zhao et al.
Sofia Bentivegna et al.
Clonal hematopoiesis of indeterminate potential (CHIP) is a condition where blood or bone marrow cells carry mutations associated with hematological malignancies. Individuals with CHIP have an increased risk of developing hematological mali...
EZH2 inhibition induces pyroptosis via RHA-mediated S100A9 overexpression in myelodysplastic syndromes [0.03%]
EZH2抑制通过RHA介导的S100A9过表达诱导骨髓增生异常综合征中的pyroptosis
Qi Zhang,Yingwan Luo,Li Ye et al.
Qi Zhang et al.
Myelodysplastic Syndromes (MDS) represent a group of heterogeneous myeloid clonal diseases derived from aberrant hematopoietic stem/progenitor cells. Enhancer of zeste homolog 2 (EZH2) is an important regulator in gene expression through me...
Telomeres, telomerase, and cancer: mechanisms, biomarkers, and therapeutics [0.03%]
端粒、端粒酶与癌症：机制、生物标志物及治疗途径
Songting Shou,Ayidana Maolan,Di Zhang et al.
Songting Shou et al.
Telomeres and telomerase play crucial roles in the initiation and progression of cancer. As biomarkers, they aid in distinguishing benign from malignant tissues. Despite the promising therapeutic potential of targeting telomeres and telomer...
Structural basis of FpGalNase and its combination with FpGalNAcDeAc for efficient A-to-O blood group conversion [0.03%]
FpGalNase及其与FpGalNAcDeAc的复合物高效实现ABO血型转换的结构基础
Meiling Zhou,Kaishan Luo,Chao Su et al.
Meiling Zhou et al.
Transfusion safety and blood typing continue to present significant challenges in clinical practice, including risks of incorrect blood transfusions and blood shortages. One promising solution is the enzymatic conversion of all red blood ce...
Construction and characterization of chimeric FcγR T cells for universal T cell therapy [0.03%]
用于通用型T细胞疗法的嵌合FcγR T细胞的构建与鉴定
Juanjuan Zhao,Manling Chen,Xudong Li et al.
Juanjuan Zhao et al.
Background: Several approaches are being explored for engineering off-the-shelf chimeric antigen receptor (CAR) T cells. In this study, we engineered chimeric Fcγ receptor (FcγR) T cells and tested their potential as a ...